Jorge Reis-Filho, Chief of AI for Science Innovation, Enterprise AI Unit, AstraZeneca, shared a post on LinkedIn:
“Computational pathology has officially moved from a “nice-to-have” to a “must-have” No longer is it an optional upgrade to the workflow; rather, it is the essential infrastructure for modern drug discovery and clinical development.
As a surgical pathologist by training, I remember vividly the days of painstakingly counting positive cells, annotating IHC slides by hand and spending hours under a microscope to identify the best avenues for targeting an individual’s cancer. Today, AI and computer vision have radically transformed the approach to discover, develop and deliver biomarkers for patient selection and treatment decision making.
The paradigm shift is from simply “reading” slides to “analyzing” data. Driven by state-of-the-art domain-specific foundation models, we can now understand tumor biology in ways that significantly improve treatment predictions. This is now a core component of patient selection strategies for both single therapies and combination regimens.
I recently joined Rob Monroe, MD, PhD from Leica Biosystems and Karan Arora from Danaher Corporation for a discussion with The Pathologist on how we are using these digital ecosystems to break through traditional bottlenecks.
To realize the impact of AI today, an ecosystem of partnerships is essential. No single stakeholder can solve this alone. We ought to collaborate and bring together domain knowledge, technical expertise and the infrastructure required to transform the patient journey.”
Other articles featuring IHC on OncoDaily.